91t 4 91f 3 These results showed : 1) Fat, Ca and hlg absorption were low in 1' 1 fed llhl but increased with postnatal age. 2) In PI fed I.II\VF, fut absorption was normal, Ca and hlg retention was higher in both studies. Elevated 1,2 5Dc repeatedly were found i n premature infants. W e investigated i f high 1,25Ik 1) a r e accompanied by a high "free 1,250H D index"(FD1 ; r a t i o molar concentrations 1,25011 D/vitnminD-2 binding protein(DBP)) and 2) a r c induced by hypophosp6atemia o r hyperparathyroidism.Matched p a i r s of 14 premature i n f a n t s ( b i r t hweight1430g,980-1700g;~,range;gestational age33weeks, 31-35wecks) were fed human milk with supplements of p h o s p h o~s ( P ) o r calcium+ P .VitanlinD 10001 .U./d were given.P,iPlll(midregional antibody) , 2501iD(RIA) ,?,25~c(RFbl) ,DBP(radial imunodiffusion) and a l k a l i n e phosphatase(AP) were measured i n serum a t bodyweights 1800+75g(I) and 2150+75g(II) ,respectively.Results were not s i g n i f i c a n t i y -d i ff e r e n t G t h i n p a i r s and therefore a r e indicated together a s x+SD: In an attempt to better understand the control of plasma 1,25-(OH)2~ concentratims cbring puberty, these concentrations have been measured i n 12 g i r l s (age 3 yr 6 mo-8 yr 10 mo) with central precocicus puherty hefore and after 3, 6 , 9, 12, 18 end 24 months of treatment with a LHRH analowe (fluserelina, Hoechst). Mean end extreme values for 1,25-(OH)2~ were 76 pg/ml (53-114) before treatment, 68 pg/ml (43-107) and 45 pg/ml (26-87) after 12 and 18-24 months of treatment respectively. N o correlation was found a t any time studied between plasma 1,25-(OH)2~ and : plasma estradiol, plasm DHAS, vaginal maturation index, hone age,hei@t gain (cm/year), plasm SmC/IGFI, serum calcium, phosphorus and alkaline phosphatase activity. Plasma 1,25(OH)2~ values were also not correlated with plasma basal LH and FSH before treatment, but were significantly correlated with plasma basal LH ( r : 0.67, p<0.02) and plasma basal FSH ( r m 0.71, p<0.01) a f t e r 12 months of treatment.
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Frm these results, me may speculate that the control of plasma 1,25-(Otl)2~ &ring puherty i s not directly dependent upon skeletal grauth, skeletal maturation and ovarian secretion but could be, a t least partially, dependent upon central factors.
AP was normal i n a l l samples.Both 1 , 2 5 k and FDI were high when compared t o a d u l t reference values but occurred without hypophosphatemia o r hyperparathyroidism. The s i g n i f i c a n c e of high t o t a l and f r e e 1,2SDc i n premature inf a n t s and t h e mechanisms of i t s regulation remain t o be e l u c idated. The syndrome of 1,25(OH)?D r e s i s t a n t r i c k e t s and a l o~e c i a has been shown t o be caused 2 ; defective receotors t o t h e a c t i v e D-metabolite (ESPE, 1982; JCEM 55:1020 JCEM 55: , 1982 . In search of a t h e r a p e u t i c approach, 7 pa l e n t s aged 2-12 years were t r e a t e d .
J ' .
On a megadose of 60 uq/m /day of laOHD f o r P months, serum 1,25(OH) 0 increased t o 1100-3000 pg/ml (normal, 20-80 pg/ml 1, but ric$e$s was not healed.
Treatment of 3 p a t i e n t s with 20 ug/m2/day of 24,25(OH)2n3.wi t h serum 24,25(OH)2D3 of 6.2-14 n4/ml (normal 1.5-4 ng/ml) f a i l e d t o heal $he r i c k e t s . With combined treatment of 24,25(OH)2D3 ?nd 30 mg/m /day i.v. calcium, r i c k e t s was not healed.
Two c h i l d r e n , 6 and 3 years o l d , received 70 mg/m2/day elementary calcium through a n intracaval c a t h e t e r , and serum calcium was maintained a t 9.1-10 mg/dl. Bone pains and muscular weakness disappeared within a week.
Serum PTH and phosphatase normalized a f t e r I and 4 months, r e s p e c t i v e l y .
X-rays dewonstrated complete healing of t h e r a c h i t i c bone changes a f t e r 4 and 6 months, respectively, and t h e c h i l d r e n ' s qrowth a c c e l e r a t e d t o 16.5 and 9.8 cmlyear, respectively. These The therapy reduced incidences of f r a c t u r e s . After 6 mth (FM, TM, G R ) and 1 y r s (FM, G R ) of treatment, BMC was s i g n i f i c a n t l y ( p C 0.01) increased. DBM showed a very slow increment of mineralization with s i g n i f i c a n t recovery only 2.7 y r s a f t e r t h e f i r s t evaluation. No adverse e f f e c t s of 1,25(0H)2D3 therapy were observed; CaU/CrU r a t i o remained in t h e normal range. Three p a t i e n t s with r i c k e t s t h a t appeared a t 1 t o 2 years old and alopecia t h a t appeared a t 2 t o 4 months old were diagnosed a t a ? e d ppphocytes of t h e s e p a t i e n t s . I n a d d i t i o n , t h e incorporation of C-thymidine i n t o PHA-stimulated lymphocytes of t h e p a t i e n t s was not reduced by 1,25-(OH) D unlike i n c o n t r o l lymphocytes. These ga4;ent.s were t r e a t e d with la-hydroxyvitamin D [la-OHD ] and calcium(Ca) l a c t a t e . Two p a t i e n t s responded t o 3 u$,/kg/day3 of la-OHD and 2 g/day of Ca l a c t a t e , and t h e i r blood chemistry and bone ?esions were normalized a f t e r 15 and 36 weeks of treatment. However, t h e most severe case responded only p a r t i a l l y t o 5 ug/kg/day of la-OHD and 2 g/day of Ca l a c t a t e . The alopecia of t h e p a t i e n t s was nat improved by t h e s e treatments. m e s e r e s u l t s suggest t h a t high doses of la-OHD may be u s e f u l i n treatment of MDR I1 with alooecia, which ha& been reported
